Pre/post-surgical investigation of some angiogenic factors due to cancer and obesity

Year 2018, , 97 - 102, 31.01.2018

Sertac Ata Guler , Atilla Yurekli Nuh Zafer Canturk Gokhan Posteki , Turgay Simsek , Ozan Can Tatar Muhittin Yurekli

https://doi.org/10.17546/msd.373798

Abstract

Objective:   Obesity is one of the important health problem for developed and developing countries. Due to literature some obesity related factors may trigger the tumor formation. For tumor development, tumoregenic cell and tissue  needs to oxygen and nutrients. Once the tumor has developed, it stimulates the angiogenesis by producing chemical signals and grows by supplied oxygen and nutrients with newly formed vessels. Aim of this study is to compare some angiogenic factors before and after surgery which will supply more information about the link between the cancer and obesity. Material and Methods: Serum samples were obtained before and 48 hours after surgery. Adrenomedullin, vascular endothelial growth factor, hipoxia inducible factor1-α and matrix metallo proteinase-2 levels were investigated in cancerous and noncancer patients. Angiogenic factors were assayed by ELISA method. Results: Higher levels of angiogenic factor were detected in cancer tissues more than in non-cancer tissues, in pre-obese and obese patients. It is seen that in humans, in post-operated patients angiogenic factors are higher in obese individuals, while non-cancer patients are also higher in obese groups and angiogenic factors which stimulate angiogenesis.  Conclusion: In the treatment of cancer, as defined previously the anti-angiogenic factors should be considered and applied as epigenetic phenomen. Due to our finding cancer related elevated angiogenic and growth factor biochemicals had been also increased in obes population and in cancer patients with surgical intervention. In the light of literature and our findings, instead of drugs, radiation therapy or surgery, which have many side effects in the treatment of cancer, we need to focus to this epigenetic phenomen for cancer patients. In general, we can say that both obesity and surgical applications lead to an increase in angiogenic factor levels, and that the healing process of wounds causes a marked increase in angiogenic factor levels

Keywords

Angiogenic Factor, Surgery, Obesity

References

• 1. Ribatti D, Djonov V. Intussusceptive microvascular growth in tumors. Cancer Lett. 2012;316:126–131.
• 2. Charnock-Jones DS, Kaufmann P, Mayhew TM. Aspects of human fetoplacental vasculogenesis and angiogenesis. I. Molecular regulation. Placenta . 2004; 25:103–113.
• 3. Girling JE, Rogers PA. Recent advances in endometrial angiogenesis research. Angiogenesis . 2005;8:89–99.
• 4. Brown MD, Hudlicka O. Modulation of physiological angiogenesis in skeletal muscle by mechanical forces: involvement of VEGF and metalloproteinases. Angiogenesis. 2003;6:1–14.
• 5. Williams JL, Weichert A, Zakrzewicz A, Da Silva-AzevedoL, Pries AR, Baum O, et al. Differential gene and protein expression in abluminal sprouting and intraluminal splitting forms of angiogenesis. Clin Sci (Lond) 2006; 110:587–5.
• 6. Gould J, Aramburo C, Capdevielle M, Scanes CG. Angiogenic activity of anterior pituitary tissue and growth hormone on the chick embryo chorio-allantoic membrane: a novel action of GH. Life Sci . 1995;56:587–594.
• 7. WHO (1998) Obesity: Preventing and managing the global epidemic. Report of a WHO consultation on obesity Geneva June 1997. Geneva: World Health Organization, HO/NUT/NCD/98:1.
• 8. Figg WDFJ. New York: Springer; 2008. Angiogenesis:an integrative approach from science to medicine.
• 9. Dome B, Hendrix MJ, Paku S, Tovari J, Timar J. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol . 2007;170:1–15.
• 10. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med . 2001;7:1194–1201.
• 11. Vihinen P, Ala-aho R, Kahari VM: Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets, 2005; 5(3): 203–20.
• 12. Liu SC et al: Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer. Clin Chim Acta, 2006; 371(1–2): 92–96.
• 13. Agnantis NJ et al: Tumor markers in cancer patients. an update of their prognostic signifi cance. Part II. In Vivo, 2004; 18(4): 481–88.
• 14. Palmer, Biff F.; Clegg, Deborah J. (2014). "Oxygen sensing and metabolic homeostasis". Molecular and Cellular Endocrinology. 397: 51–57.
• 15. Semenza GL (Apr 2000). "HIF-1: mediator of physiological and pathophysiological responses to hypoxia". Journal of Applied Physiology. 88 (4): 1474–80.
• 16. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10): 721–732.
• 17. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, Matsuda M, Shimomura I. Adipose Tissue Hypoxia in Obesity and Its Impact on Adipocytokine Dysregulation. Diabetes 2007 Apr; 56(4): 901-911.
• 18. Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O , Lavaut MN, Allasia C, Bonnier P, Charpin C. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer. 2005 Sep 20;116(5):734-9.
• 19. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T: Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993, 192: 553-560.
• 20. Hinson JP, Kapas S, Smith DM: Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000, 21: 138-167.
• 21. Lopez J, Martinez A: Cell and molecular biology of the multifunctional peptide, adrenomedullin. Int Rev Cytol. 2002, 221: 1-92.
• 22. Larrazoy IM, Martinez-Herrero S, GArcia-Sanmartin J, Ochoa-Callejero L, Martinez A. Adrenomedullin and tumour microenvironment. J Transl Med. 2014, 12:339.
• 23 Yurekli M, Culum AA. The investigation of relationship between adrenomedullin vascular growth endothelial factor in obese and calorie restricted rats. Medical Science and Discovery 2016, 3(3): 124-9.
• 24. Belizon A, Balik E, Feingold DL, Bessler M, Arnell TD, Forde KA, Horst PK, Jain S, Cekic V, Kirman I, Whelan RI. Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods. Ann Surg. 2006; 244(5):792-798.
• 25. Kong B, Michalski CW, Friess H, Kleeff J. Surgical procedure as an inducer of tumor angiogenesis. Exp Oncol. 2010 Sep;32(3):186-9.
• 26. Jarmila D.W. van der Bilt, Inne H.M. Borel Rinkes. Surgery and angiogenesis. Surgery and angiogenesis. Biochimica et Biophysica Acta 1654 (2004) 95–104.
• 27. Cao Y, Future options of anti-angiogenic cancer therapy. Chinese Journal of Cancer 2016, 35:21
• 28. Jessica M. Castañeda-Gill and Jamboor K. Vishwanatha. Antiangiogenic mechanisms and factors in breast cancer treatment. J Carcinog. 2016; 15: 1.
• 29. Vasudev NS, Reynolds AR. Anti‐angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 2014; 17 (3): 471-494
• 30. Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity. Physiol Rev. 2013 Jan;93(1):1-21